Castle Biosciences' (CSTL) Q1 2025 EPS forecast is not currently available. However, we can analyze the company's recent financial performance and trends to provide insights into what the forecast might indicate.
- Recent Financial Performance:
- In 2024, Castle Biosciences reported a significant revenue increase of 51% year-over-year, reaching $332 million12.
- The company delivered 96,071 test reports, marking a 36% increase compared to the previous year2.
- Castle Biosciences achieved a gross margin of 79% and an adjusted gross margin of 82%, both showing improvement from the previous year2.
- The company reported a net income of $18.2 million, a substantial turnaround from a net loss of $57.5 million in 202312.
- Adjusted EBITDA also saw a significant rise to $75 million from a negative $4.4 million in 202312.
- Trends and Challenges:
- Despite the strong growth, Castle Biosciences faces challenges such as the potential loss of Medicare coverage for DecisionDx-SCC and expected declines in the mental health segment1.
- The company's EPS has shown variability in the past, with a significant beat in the Q3 2024 earnings report where EPS was 0.08,beatingtheconsensusestimateof-0.06 by $0.1434.
- Analyst Expectations and Price Target:
- Analysts have set an average price target of $41.50 for CSTL, with a high forecast of $44.00 and a low forecast of $40.00, indicating a potential upside from the current price5.
- CSTL has a track record of beating EPS estimates, with an 81.0% beat rate in Q4 2023, and a 100.00% beat rate in the past 12 months67.
Given these points, while a specific EPS forecast for Q1 2025 is not available, the company's strong revenue growth, improved profitability, and positive analyst sentiment suggest that the EPS forecast may be positive. However, the potential challenges and variability in EPS indicate that the actual EPS may fall within a range that is in line with the company's historical performance and market conditions.
4/10/2025 07:22am
